Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron to Host KOL Webinar on the Potential of Clever-1 Receptor as a Target for Macrophage-Guided Immunotherapy on July 19, 2021 TURKU, FINLAND / BOSTON, MA, July 12, 2021 – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that it will host a webinar entitled ‘Clever-1 as a target for macrophage-guided immunotherapy’ on Monday 19 July